Azomyr 5 mg orodispersible tablets

Azomyr orodispersible tablet is an antiallergy medicine that does not make you drowsy. It helps control your allergic reaction and its symptoms.

Azomyr orodispersible tablet relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites). These symptoms include sneezing, runny or itchy nose, itchy palate, and itchy, red or watery eyes.

Azomyr orodispersible tablet is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy). These symptoms include itching and hives.

Relief of these symptoms lasts a full day and helps you to resume your normal daily activities and sleep.

Do not take Azomyr orodispersible tablet

• if you are allergic (hypersensitive) to desloratadine, or any of the other ingredients of Azomyr orodispersible tablet, or to loratadine.

Azomyr 5 mg orodispersible tablet is indicated for adults and adolescents (12 years of age and older).

Take special care with Azomyr orodispersible tablet

• if you have poor kidney function.

If this applies to you, or if you are not sure, please check with your doctor before taking Azomyr.

Taking other medicines
There are no known interactions of Azomyr with other medicines.

Taking Azomyr orodispersible tablet with food and drink
Azomyr orodispersible tablet does not need to be taken with water or liquid. Additionally, Azomyr orodispersible tablet may be taken with or without a meal.

Pregnancy and breast-feeding

Ask your doctor or pharmacist for advice before taking any medicine during pregnancy and breast-

feeding.

If you are pregnant or nursing a baby, taking Azomyr is not recommended.

Driving and using machines
At the recommended dose, Azomyr is not expected to cause you to be drowsy or less alert. However, very rarely some people experience drowsiness, which may affect their ability to drive or use machines.

Important information about some of the ingredients of Azomyrorodispersible tablet This product contains aspartame. Aspartame is a source of phenylalanine, which may be harmful for people with phenylketonuria.

Before using, carefully peel open the blister and remove the dose of orodispersible tablet without crushing it. Place it in your mouth and it will disperse immediately. Water or other liquid is not needed to swallow the dose.

Adults and adolescents (12 years of age and older): take one 5 mg Azomyr orodispersible tablet once a day. Take the dose immediately after removal from the blister.

Regarding the duration of treatment, your physician will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Azomyr orodispersible tablets. If your allergic rhinitis is intermittent (presence of symptoms for less than 4 days per week or for less than 4 weeks), your physician will recommend you a treatment schedule that will depend on the evaluation of the history of your disease.
If your allergic rhinitis is persistent (presence of symptoms for 4 days or more per week and for more than 4 weeks), your physician may recommend you a longer term treatment.

For urticaria, the duration of treatment may be variable from patient to patient and therefore you should follow the instructions of your physician.

If you take more Azomyr orodispersible tabletthan you should
Take Azomyr orodispersible tablet only as prescribed for you. No serious problems are expected with accidental overdose. However, if you take more Azomyr orodispersible tablet than you were told to, contact your doctor or pharmacist.

If you forget to take Azomyr orodispersible tablet
If you forget to take your dose on time, take it as soon as possible, then go back to your regular dosing schedule. Do not take a double dose to make up for forgotten individual doses.

Like all medicines, Azomyr can cause side effects although not everybody gets them. In adults, side effects were about the same as with a dummy tablet. However, fatigue, dry mouth and headache were reported more often than with a dummy tablet. In adolescents, headache was the most commonly reported side effect.

During the marketing of Azomyr, cases of severe allergic reactions (difficulty in breathing, wheezing, itching, hives and swelling) and rash have been reported very rarely. Cases of palpitations, rapid heartbeat, stomach pain, nausea (feeling sick), vomiting, upset stomach, diarrhoea, dizziness, drowsiness, inability to sleep, muscle pain, hallucinations, seizures, restlessness with increased body movement, liver inflammation and abnormal liver function tests have also been reported very rarely.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please

tell your doctor or pharmacist.

Keep out of the reach and sight of children.

Store in the original package.

Do not use Azomyr orodispersible tablet after the expiry date which is stated on the carton and blister. The expiry date refers to the last day of that month.

Tell your pharmacist if you notice any change in the appearance of Azomyr orodispersible tablet.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

What Azomyr orodispersible tablet contains

• The active substance is desloratadine 5 mg
• The other ingredients are microcrystalline cellulose, pregelatinized starch, sodium starch glycolate, magnesium stearate, butylated methacrylate copolymer, crospovidone, sodium hydrogen carbonate, citric acid, colloidal silicon dioxide, ferric oxide, mannitol, aspartame (E951) and flavour Tutti-Frutti.

What Azomyr orodispersible tablet looks like and contents of the pack

Azomyr 5 mg orodispersible tablet is light red, speckled, and round with ?A? branded on one side. Azomyr orodispersible tablet is packed in unit dose blisters in packs of
5, 6, 10, 12, 15, 18, 20, 30, 50, 60, 90 and 100 doses of orodispersible tablet.
Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder: SP Europe, Rue de Stalle 73, B-1180 Bruxelles, Belgium.

Manufacturer: SP Labo N.V., Industriepark 30, B-2220 Heist-op-den-Berg, Belgium.

For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:

BelgiëBelgiqueBelgien Rue de StalleStallestraat 73 B-1180 BruxellesBrusselBrüssel TélTel 32-02 370 92 11 LuxembourgLuxemburg Rue de Stalle 73 B-1180 BruxellesBrüssel BelgiqueBelgien TélTel 32-02 370 92 11

. 359 2 819 3737 info-msdbgmerck.com .Magyarország Alkotás u. 53. H-1123 Budapest Tel. 36 1 457-8500

eská republika Ke tvanici 3 CZ-186 00 Praha 8 Tel 420 221771250 Malta Associated Drug Co. Ltd. Triq l-Esportaturi Mriehel Birkirkara BKR 3000 Tel. 35622778000

Danmark Lautrupbjerg 2 DK-2750 Ballerup Tlf 45-44 39 50 00 Nederland Merck Sharp Dohme BV Tel 31 0800 9999000 31 23 5153153 medicalinfo.nlmerck.com

Norge Pb. 398 N-1326 Lysaker Tlf 47 67 16 64 50 Deutschland Thomas-Dehler-Straße 27 D-81737 München Tel 49-089 627 31-0 Infoessex-pharma.de

Eesti A. H. Tammsaare tee 47 EE-11316 Tallinn Tel 372 6139 750 Österreich Merck Sharp Dohme Ges.m.b.H. Tel 43 0 1 26 044 msd-medizinmerck.com

MSD ..... 30 210 98 97 300 cora.greece.gragcmmerck.com Polska POLPHARMA Biuro Handlowe Sp. z o.o. Ul. Bobrowiecka 6 00-728 Warszawa Tel. 022 364 61 01

Portugal Rua Agualva dos Açores 16 P-2735-557 Agualva-Cacém Tel 351-21 433 93 00 España Laboratorios Menarini S.A. CAlfonso XII, 587 E-08918 - Badalona Barcelona Tel 34-93 462 88 00

France 34 avenue Léonard de Vinci F-92400 Courbevoie Tél 33-01 80 46 40 40 România os. Bucureti-Ploieti, nr. 17-21, Bneasa Center, et. 8, sector 1 RO-013682 Bucureti Tel. 40 21 233 35 30

Slovenija Dunajska 22 SI-1000 Ljubljana Tel 386 01 3001070 Ireland Merck Sharp and Dohme Ireland Human Health Limited Tel 353 01 2998700 medinfoirelandmerck.com

Ísland Hörgatún 2 IS-210 Garðabær Sími 354 535 70 00 Slovenská republika Strakova 5 SK-811 01 Bratislava Tel 421 2 5920 2712

Italia Via fratelli Cervi snc, Centro Direzionale Milano Due Palazzo Borromini .SuomiFinland PL 46PB 46 FIN-02151 EspooEsbo PuhTel 358 09 804 650 I-20090 Segrate Milano Tel 39-02 21018.1

Merck Sharp Dohme Cyprus Limited . 800 00 673 357 22866700 cyprusinfomerck.com Sverige Merck Sharp Dohme Sweden AB Tel 46 77 5700488 medicinskinfomerck.com

Latvija Skanstes iela 13 Rga, LV-1013 Tel 371-67364224 United Kingdom Merck Sharp and Dohme Limited Tel 44 0 1992 467272 medicalinformationukmerck.com

Lietuva

K-stu-io g. 59/27
LT-08124 Vilnius
Tel. + 370 52 101868

This leaflet was last approved on